A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Combination with Serplulimab with or Without Platinum-based Chemotherapy in Selected Subjects with Advanced Solid Tumors
Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
A PHASE1 clinical study on Advanced Solid Tumors, this trial is actively recruiting participants. The trial is conducted by MediLink Therapeutics (Suzhou) Co., Ltd. and has accumulated 7 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE1
-
Mar 2025 — Sep 2025 [monthly]
Recruiting PHASE1
-
Jan 2025 — Mar 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Apr 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MediLink Therapeutics (Suzhou) Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changhua, China , Changsha, China , Chengdu, China , Chongqing, China , Fuzhou, China , Guangzhou, China , Haikou, China , Hangzhou, China , Harbin, China and 13 more locations